



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_100_24

You asked:

I have a freedom of information request.

1. How many patients have been treated with the following drugs in the past 4 months:

- **Atogepant (Aquipta) – any disease**
- **Erenumab (Aimovig) - any disease**
- **Eptinezumab (Vyepti) – any disease**
- **Fremanezumab (Ajovy) - any disease**
- **Galcanezumab (Emgality) - any disease**
- **Rimegepant (Vydura) – any disease**
- **Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY**

Please find below two tables populated with the data that Medicines Management are able to provide in relation to your enquiry. The period relates to the last 4 months available which is 1st October 2023 to 31st January 2024.

Unfortunately, we are unable to provide Botulinum Toxin data by patient number and by condition because not all the issues are made to individual patients and the Pharmacy Electronic Dispensing system does not record the condition being treated. However, we have provided Botulinum Toxin information by number of issues.

Medicine	Number of Patients
Atogepant (Aquipta) – any disease	0
Erenumab (Aimovig) - any disease	8
Eptinezumab (Vyepti) – any disease	0
Fremanezumab (Ajovy) - any disease	49
Galcanezumab (Emgality) - any disease	6
Rimegepant (Vydura) – any disease	11

Medicine	Pack Size	Number of Issues
Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - any condition		
BOTULINUM TOXIN TYPE A (BOTOX) 100 units Injection	1 Vial Pack	108
BOTULINUM TOXIN TYPE A (BOTOX) 200 units Injection	1 Vial Pack	55

BOTULINUM TOXIN TYPE A (BOTOX) 50 units Injection	1 Vial Pack	57
BOTULINUM TOXIN TYPE A (DYSPORT) 300 units Injection	1 Vial Pack	2
BOTULINUM TOXIN TYPE A (DYSPORT) 500 units Injection	2 Vial Pack	7
BOTULINUM TOXIN TYPE A (XEOMIN) 100 units Injection	1 Vial Pack	5
BOTULINUM TOXIN TYPE A (XEOMIN) 50 units Injection	1 Vial Pack	25

2. How many patients have you treated in the last 4 months for chronic migraine (15+ headache days per month) and episodic migraine (4-15 headache days per month) with the following drugs:

Drugs	Chronic Migraine (15+ headache days per month)	Episodic Migraine (4-15 headache days per month)
Atogepant		
Erenumab		
Eptinezumab		
Fremanezumab		
Galcanezumab		
Rimegepant		
Botulinum Toxin		

We can confirm that the Health Board does not centrally record this information. The information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.

3. Does the trust actively initiate a treatment pause (usually at 12 months) of anti-CGRP (calcitonin gene-related peptide inhibitors) migraine treatment with the aim to re-start treatment if the patient continues to fit the criteria (Yes/No)?

A treatment pause is routinely considered as part of follow-up, usually sometime between 6-12 months, but the decision on whether to proceed or not with such a pause is made on individual patient bases rather than as a blanket policy.